Eli Lilly and Co. (LLY) Shares Bought by Calamos Advisors LLC
Calamos Advisors LLC raised its stake in Eli Lilly and Co. (NYSE:LLY) by 0.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 432,822 shares of the company’s stock after buying an additional 37 shares during the period. Calamos Advisors LLC’s holdings in Eli Lilly and were worth $34,085,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Renaissance Technologies LLC increased its position in shares of Eli Lilly and by 565.1% in the first quarter. Renaissance Technologies LLC now owns 2,213,605 shares of the company’s stock valued at $159,402,000 after buying an additional 1,880,800 shares during the last quarter. Beutel Goodman & Co Ltd. acquired a new position in shares of Eli Lilly and during the second quarter valued at approximately $104,345,000. Bank of Montreal Can acquired a new position in shares of Eli Lilly and during the second quarter valued at approximately $86,545,000. Franklin Resources Inc. increased its position in shares of Eli Lilly and by 3.6% in the first quarter. Franklin Resources Inc. now owns 27,744,978 shares of the company’s stock valued at $1,997,920,000 after buying an additional 961,204 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. acquired a new position in shares of Eli Lilly and during the first quarter valued at approximately $61,280,000. 74.96% of the stock is owned by hedge funds and other institutional investors.
Eli Lilly and Co. (NYSE:LLY) traded up 0.65% during midday trading on Friday, reaching $80.26. The company had a trading volume of 3,622,982 shares. Eli Lilly and Co. has a 12-month low of $67.88 and a 12-month high of $88.48. The stock has a market capitalization of $84.89 billion, a PE ratio of 34.59 and a beta of 0.20. The company has a 50-day moving average of $79.23 and a 200-day moving average of $77.11.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, July 26th. The company reported $0.86 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.86. Eli Lilly and had a return on equity of 23.99% and a net margin of 11.97%. The firm had revenue of $5.40 billion for the quarter, compared to analysts’ expectations of $5.14 billion. During the same period in the previous year, the firm earned $0.90 earnings per share. The business’s revenue was up 8.6% compared to the same quarter last year. On average, analysts predict that Eli Lilly and Co. will post $3.59 EPS for the current fiscal year.
LLY has been the subject of several recent research reports. Morgan Stanley reaffirmed a “hold” rating and issued a $88.00 price objective on shares of Eli Lilly and in a research note on Saturday, June 4th. SunTrust Banks Inc. reaffirmed a “buy” rating on shares of Eli Lilly and in a research note on Wednesday, June 15th. Leerink Swann reaffirmed a “buy” rating on shares of Eli Lilly and in a research note on Sunday, June 26th. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Eli Lilly and in a research note on Tuesday, June 28th. Finally, Jefferies Group upped their price objective on Eli Lilly and from $100.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, July 14th. Two equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $97.16.
In other Eli Lilly and news, Director Jackson P. Tai bought 2,560 shares of Eli Lilly and stock in a transaction dated Friday, August 12th. The shares were purchased at an average cost of $80.42 per share, with a total value of $205,875.20. Following the completion of the purchase, the director now owns 42,110 shares of the company’s stock, valued at $3,386,486.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Donald A. Zakrowski sold 1,213 shares of the business’s stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $83.16, for a total value of $100,873.08. Following the transaction, the insider now directly owns 1,300 shares in the company, valued at $108,108. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related stocks with our FREE daily email newsletter.